Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ARCHIVE
ARCHIVE
- Speakers at CPhI Japan 2011 Agree on Prospects for Growth in Vaccine Market
July 25, 2011
- 12 APIs Including Lixiana Added to NHI Price List
July 25, 2011
- PFSB Taking Public Comments on Revision of GLs for Equivalence Testing of Generic Drugs
July 25, 2011
- Pharmacy, Drugstore Industries Intensifying Efforts to Ensure Compliance with Regulations
July 25, 2011
- Korosho to Improve List of Accredited Foreign Drug Manufacturers
July 25, 2011
- Generics Account for 23.5% of Total Number of Drugs in 2010: Korosho Survey
July 25, 2011
- Psychiatric Disease to Be Added to 4 Designated Diseases in Healthcare Planning System
July 25, 2011
- Infrastructure Needed to Promote Orphan Drug Development: Health Minister Hosokawa
July 25, 2011
- Rate of Generic Drug Use Declined in February, March: Survey
July 25, 2011
- Korosho to Promote Anti-HTLV-1 Measures
July 25, 2011
- Director Yoshida Warns Pharmacies about Gov't Taking Harsh Stance on Dispensing Fees
July 25, 2011
- 85% of Doctors Uneasy about Prescribing Generics: MedPeer Survey
July 25, 2011
- State Subsidy Recommended for MSD's HPV Vaccine Gardasil
July 25, 2011
- LDP Subcommittee Holds Hearing on Unification of Dispensing Fees
July 25, 2011
- “Biosimilars Era”Coming to Japan: Mr Sawai of JGA
July 25, 2011
- JPA to Collect ADR Avoidance Case Reports from Pharmacies
July 25, 2011
- Merck Serono to Enter 2nd High Growth Stage after Stable Growth in 2011-2012: President Smith
July 25, 2011
- No Major Obstacle to Japan's Participation in PIC/S: Chairman Graberg
July 25, 2011
- Teva Obtains All Shares from Taiyo Pharm. for ¥74 Bil.
July 25, 2011
- APEX to Build Up Nationwide Network
July 25, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…